Repligen (NASDAQ:RGEN) Given New $210.00 Price Target at Benchmark

Repligen (NASDAQ:RGEN – Get Rating) had its price objective cut by research analysts at Benchmark from $230.00 to $210.00 in a research report issued on Wednesday, The Fly reports. Benchmark’s target price points to a potential upside of 33.56% from the stock’s previous close. A number of other equities research analysts also recently weighed in […]

Related Keywords

United States ,America ,Stifel Nicolaus ,Craig Hallum ,Macquarie Group Ltd ,Repligen Corp ,Norges Bank ,Pricet Rowe Associates Inc ,Sands Capital Management ,Repligen Company Profile ,Keycorp ,Get Rating ,Capital Management ,Macquarie Group ,Asia Pacific Region ,Repligen Daily ,Repligen ,Nasdaq Rgen ,Rgen ,Medical ,75991610 ,Lower Price Target ,Benchmark Co ,